DGAP-Adhoc: WILEX AG: Nuclea Biotechnologies Inc. acquires WILEX Inc. and extends their cooperation with WILEX AG

WILEX AG / Key word(s): Strategic Company Decision/Disposal

06.09.2013 18:46

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad hoc release pursuant to § 15 Wertpapierhandelsgesetz
(German Securities Trading Act)

Nuclea Biotechnologies Inc. acquires WILEX Inc. and extends their
cooperation with WILEX AG

Munich, Germany, 06. September 2013. WILEX AG (ISIN DE0006614720/ WL6 /
FSE) and Nuclea Biotechnologies, Inc., Pittsfield, MA, USA, (Nuclea) today
signed a share deal and development agreement. Nuclea acquires all shares
of WILEX Inc., Cambridge, MA, USA, (Oncogene Science), a wholly owned US
subsidiary of WILEX AG.

Nuclea will in return assume responsibility for repayment of USD 2.5
million under an intercompany loan between WILEX Inc. and WILEX AG. In
addition, WILEX AG is eligible for single-digit royalties on net sales on
the HER-2/neu and CAIX assays.

Concurrently and as essential part of the overall deal, WILEX AG and Nuclea
entered into a development agreement under which Nuclea will develop an
automated CAIX IVD IHC assay ('CAIX Dx') to be submitted for FDA allowance
under the investigational device exemption ('IDE'). This CAIX Dx is
intended to be used for patient stratification in a planned pivotal study
with RENCAREX(R) and as a potential future companion diagnostic in the
adjuvant treatment of clear cell renal cell carcinoma. Nuclea will bear the
costs for the development of this CAIX Dx as a contribution in kind which
will lead to savings of at least USD 2.5 million for WILEX AG.

Nuclea and WILEX Inc. have been partners in marketing the serum HER-2/neu
ELISA since early 2013. Today's agreement includes the transfer to Nuclea
of numerous distribution and marketing agreements for all marketed Oncogene
Science biomarker tests (HER-2/neu ELISA, CAIX assays and other Research
Use Only tests) which complement Nuclea's wide range of products and
services.

---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

About Nuclea
Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts
with additional operations in Worcester, Massachusetts. Nuclea has
developed and is commercializing unique diagnostic tests for colon, breast,
leukaemia, lung and prostate cancer. Nuclea also performs research leading
to novel molecular oncology companion diagnostics for the pharmaceutical
and biotechnology industries. www.nucleabio.com

About WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG, Munich, Germany.
The team of 11 employees has many years' experience in developing and
manufacturing biomarker tests for oncology, which are marketed under the
brand name Oncogene Science. The product portfolio includes enzyme-linked
immunosorbent assays (ELISA) and immunohistochemical (IHC) assays for in
vitro diagnostic (IVD) and research use only (RUO). With the aim of
supporting treatment regimens for cancer patients worldwide WILEX Inc.
offers biomarker tests for measuring oncogenes, growth factor receptors
(HER-2/neu, EGFR), proteases and protease inhibitors (uPA, PAI-1, TIMP-1),
as well as markers of hypoxia (CAIX). WILEX Inc. is based in Cambridge, MA,
USA and also provides GMP and ISO certified manufacturing services. More
information is available at www.oncogene.com.

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused
on oncology, the Company develops diagnostic and therapeutic product
candidates for the specific detection and targeted treatment of various
types of cancer based on antibodies and small molecules. The subsidiary
Heidelberg Pharma GmbH offers preclinical contract research services and an
antibody drug conjugate (ADC) technology platform. The business model
comprises research and product development as well as the commercialisation
of its activities. Our customers and partners include leading international
pharmaceutical companies. WILEX AG is listed at the Frankfurt Stock
Exchange. ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is
available at www.wilex.com.

Contact

Corporate Communications
Katja Arnold (CIRO) & Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Mobil: +49 (0)160 93 60 30 22
Email: investors[at]wilex.com

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects',
'may', 'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial position, earnings, achievements, or industry results, to be
materially different from any future results, earnings or achievements
expressed or implied by such forward-looking statements. Given these
uncertainties, prospective investors and partners are cautioned not to
place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

---------------------------------------------------------------------------

Language: English
Company: WILEX AG
Grillparzerstr. 10
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE0006614720
WKN: 661472
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------